TuisIONS • NASDAQ
add
Ionis Pharmaceuticals Inc
Vorige sluiting
$48,18
Dagwisseling
$47,35 - $48,39
Jaarwisseling
$35,95 - $54,44
Markkapitalisasie
6,95 mjd USD
Gemiddelde volume
1,19 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Jun. 2024info | J/J-verandering |
---|---|---|
Inkomste | 225,25 m | 19,55% |
Bedryfskoste | 65,11 m | 41,11% |
Netto inkomste | -66,26 m | 22,31% |
Netto winsgrens | -29,42 | 35,01% |
Wins per aandeel | -0,24 | 40,89% |
EBITDA | -63,00 m | 27,53% |
Effektiewe belastingkoers | -0,10% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Jun. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 2,09 mjd | -12,87% |
Totale bates | 2,69 mjd | -9,42% |
Totale aanspreeklikheid | 2,43 mjd | -4,54% |
Totale ekwiteit | 263,70 m | — |
Uitstaande aandele | 146,21 m | — |
Prys om te bespreek | 26,62 | — |
Opbrengs op bates | -6,06% | — |
Opbrengs op kapitaal | -7,30% | — |
Kontantvloei
Netto kontantverandering
(USD) | Jun. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -66,26 m | 22,31% |
Kontant van bedrywe | -119,88 m | -23,13% |
Kontant van beleggings | 62,45 m | -10,16% |
Kontant van finansiering | 2,56 m | -98,22% |
Netto kontantverandering | -54,90 m | -147,42% |
Beskikbare kontantvloei | -101,02 m | -120,17% |
Meer oor
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra, and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Gestig
1989
Hoofkwartier
Webwerf
Werknemers
927